Yes. 18 FDA-approved labels for Lamivudine carry a boxed warning, and its subject is exacerbations of hepatitis b, and different formulations of lamivudine tablets. exacerbations of hepatitis b severe. A boxed warning is the most serious warning the FDA requires on a prescription label. It is applied to the drug and to the situations in which it is used, not to any particular person taking it.
What the warning says
Below is how the Lamivudine warning opens on one specific label, identified underneath it. Of the 18 Lamivudine labels sampled, 11 carried materially different wordings, and this was the most common, used by 4 of them.
WARNING: EXACERBATIONS OF HEPATITIS B, AND DIFFERENT FORMULATIONS OF LAMIVUDINE TABLETS. Exacerbations of Hepatitis B Severe acute exacerbations of hepatitis B have been reported in patients who are co-infected with hepatitis B virus (HBV) and human immunodeficiency virus (HIV-1) and have discontinued lamivudine tablets. Hepatic function should be monitored closely with both clinical and laboratory follow-up for at least several months in patients who discontinue lamivudine tablets and are co-infected with HIV-1 and HBV. If appropriate, initiation of anti-hepatitis B therapy may be warranted [see Warnings and Precautions ( 5.1 )].
LAMIVUDINE, Apotex Corp., label version effective 19 September 2025. Opening of the warning; read the full label on DailyMed.Why the wording differs between manufacturers
There is no single official text of a boxed warning. The FDA sets what a warning must cover, and each manufacturer writes its own label within that. Of the 18 Lamivudine labels sampled for this page, 11 carried materially different wordings of the same warning, and the version quoted above was used by 4 of them.
The hazard does not change between those 11 versions. Only the sentences do, which is why a refill from a different manufacturer can carry warning text that reads differently without anything about Lamivudine or its risks having changed.
Lamivudine is dispensed under 18 current FDA labels despite this warning, which is the point worth holding onto: a boxed warning is a disclosure requirement, not a verdict. What a boxed warning does and does not mean sets out the distinction.
Common questions
Does Lamivudine have a black box warning?
Yes. 18 FDA-approved labels for Lamivudine carry a boxed warning, and its subject is exacerbations of hepatitis b, and different formulations of lamivudine tablets. exacerbations of hepatitis b severe. A boxed warning is the strongest warning the FDA requires on a prescription label, and it is applied to the drug, not to any individual taking it.
What does the Lamivudine boxed warning say?
The wording is set by each manufacturer within FDA requirements, so it varies. In the version quoted on this page, taken from a label effective 19 September 2025, the warning concerns exacerbations of hepatitis b, and different formulations of lamivudine tablets. exacerbations of hepatitis b severe. The full text is linked so the exact version can be read rather than summarised.
Does the Lamivudine boxed warning mean the drug is unsafe or being withdrawn?
No. It means the FDA requires the risk of exacerbations of hepatitis b, and different formulations of lamivudine tablets. exacerbations of hepatitis b severe to be communicated prominently so prescribers weigh it explicitly. Lamivudine remains FDA-approved and is dispensed under 18 current labels. A boxed warning is a disclosure requirement, not a judgement that a drug should not be used.
Why do different pharmacies show different warning text for the same drug?
Because each manufacturer writes its own label within the FDA's requirements. Of 18 Lamivudine labels sampled here, 11 carried materially different wordings of the same warning. The hazard described is the same; the sentences are not. This is a common source of confusion when a prescription is refilled with a different manufacturer's product.
Should I stop taking Lamivudine because of this warning?
This page does not answer that and cannot. The warning about exacerbations of hepatitis b, and different formulations of lamivudine tablets. exacerbations of hepatitis b severe is written for a prescriber deciding whether Lamivudine suits a particular patient, and stopping a prescribed medicine carries its own risks that this page knows nothing about. Raise it with the prescriber or a pharmacist, who can see the whole picture.
Where this page's information comes from
The quotation above is from one Lamivudine label, linked below by its DailyMed set identifier so the exact version can be opened rather than taken on trust. The figure of 18 labels, and the count of 11 distinct wordings among 18 sampled, were computed from the openFDA labelling API on 30 August 2026.
- LAMIVUDINE prescribing information, Apotex Corp., effective 19 September 2025.
- openFDA drug labelling API, the source of the label counts and variant counts on this page.
Labels are revised over time. The version linked above is the one this page was written against, and a newer revision may differ. Counts reflect the labels present in openFDA on the retrieval date.